Inhibition of human catechol-O-methyltransferase-mediated dopamine O-methylation by daphnetin and its Phase II metabolites

References

• Antonio L, Grillasca JP, Taskinen J, et al. (2002). Characterization of catechol glucuronidation in rat liver. Drug Metab Dispos 30:199–207
   PubMed Web of Science ®Google Scholar
• Assal F, Spahr L, Hadengue A, et al. (1998). Tolcapone and fulminant hepatitis. Lancet 352:958
   PubMed Web of Science ®Google Scholar
• Bonifácio MJ, Torrão L, Loureiro AI, et al. (2015). Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. Br J Pharmacol 172:1739–52
   PubMed Web of Science ®Google Scholar
• Boudet AM. (2007). Evolution and current status of research in phenolic compounds. Phytochemistry 68:2722–35
   PubMed Web of Science ®Google Scholar
• Chen D, Wang Y, Lambert JD, et al. (2005). Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies. Biochem Pharmacol 69:1523–31
   PubMed Web of Science ®Google Scholar
• Cheng X, Roberts RJ. (2001). AdoMet-dependent methylation, DNA methyltransferases and base flipping. Nucleic Acids Res 29:3784–95
   PubMed Web of Science ®Google Scholar
• Dingemanse J, Jorga K, Zürcher G, et al. (1995). Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 40:253–62
   PubMed Web of Science ®Google Scholar
• Ellermann M, Paulini R, Jakob-Roetne R, et al. (2011). Molecular recognition at the active site of catechol-O-methyltransferase (COMT): adenine replacements in bisubstrate inhibitors. Chemistry 17:6369–81
   PubMed Web of Science ®Google Scholar
• Fisher A, Croft-Baker J, Davis M, et al. (2002). Entacapone-induced hepatotoxicity and hepatic dysfunction. Mov Disord 17:1362–5
   PubMed Web of Science ®Google Scholar
• Ge GB, Liang SC, Fang ZZ, Yang L. (2010). Rapid metabolite profiling of in vivo metabolites of escultin in rat using ultra-fast liquid chromatography combined with tandem mass spectrometry. Drug Metab Rev 42:214
   Web of Science ®Google Scholar
• Hauser RA, Zesiewicz TA. (1999). Management of early Parkinson’s disease. Med Clin North Am 83:393–14
   PubMed Web of Science ®Google Scholar
• Hurtado-Fernández E, Gómez-Romero M, Carrasco-Pancorbo A, Fernández-Gutiérrez A. (2010). Application and potential of capillary electroseparation methods to determine antioxidant phenolic compounds from plant food material. J Pharm Biomed Anal 53:1130–60
   PubMed Web of Science ®Google Scholar
• Jatana N, Apoorva N, Malik S, et al. (2013). Inhibitors of catechol-O-methyltransferase in the treatment of neurological disorders. Cent Nerv Syst Agents Med Chem 13:166–94
   PubMedGoogle Scholar
• Jiang HM, Fang ZZ, Cao YF, et al. (2013). New insights for the risk of bisphenol A: inhibition of UDP-glucuronosyltransferases (UGTs). Chemosphere 93:1189–93
   PubMed Web of Science ®Google Scholar
• Keränen T, Gordin A, Harjola VP, et al. (1993). The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 16:145–56
   PubMed Web of Science ®Google Scholar
• Lautala P, Ulmanen I, Taskinen J. (2001). Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. Mol Pharmacol 59:393–402
   PubMed Web of Science ®Google Scholar
• Liang SC, Ge GB, Liu HX, et al. (2010). Identification and characterization of human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of daphnetin. Drug Metab Dispos 38:973–80
   PubMed Web of Science ®Google Scholar
• Liang SC, Ge GB, Xia YL, et al. (2015). In vitro evaluation of the effect of 7-methyl substitution on glucuronidation of daphnetin: metabolic stability, isoform selectivity, and bioactivity analysis. J Pharm Sci 104:3557–64
   PubMed Web of Science ®Google Scholar
• Liang SC, Xia YL, Hou J, et al. (2016). Methylation, glucuronidation, and sulfonation of daphnetin in human hepatic preparations in vitro: metabolic profiling, pathway comparison, and bioactivity analysis. J Pharm Sci 105:808–16
   PubMed Web of Science ®Google Scholar
• Lundström K, Salminen M, Jalanko A, et al. (1991). Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol 10:181–9
   PubMed Web of Science ®Google Scholar
• Ma Z, Liu H, Wu B. (2014). Structure-based drug design of catechol-O-methyltransferase inhibitors for CNS disorders. Br J Clin Pharmacol 77:410–20
   PubMed Web of Science ®Google Scholar
• Männistö PT, Kaakkola S. (1999). Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51:593–28
   PubMed Web of Science ®Google Scholar
• Martin JL, McMillan FM. (2002). SAM (dependent) I AM: the S-adenosylmethionine-dependent methyltransferase fold. Curr Opin Struct Biol 12:783–93
   PubMed Web of Science ®Google Scholar
• Peitzsch M, Prejbisz A, Kroiß M, et al. (2013). Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma. Ann Clin Biochem 50:147–55
   PubMed Web of Science ®Google Scholar
• Pystynen J, Ovaska M, Vidgren J, et al. (2002). Coumarin derivatives with COMT inhibiting activity. WO2002/02548 A1
   Google Scholar
• Qu SY, Wu YJ, Wang YH, Zuo YX. (1983). Metabolism and pharmacokinetics of daphnetin. Yao Xue Xue Bao 18:496–500
   PubMedGoogle Scholar
• Riveiro ME, De Kimpe N, Moglioni A, et al. (2010). Coumarins: old compounds with novel promising therapeutic perspectives. Curr Med Chem 17:1325–38
   PubMed Web of Science ®Google Scholar
• Shan JJ. (2009). Studies on oral absorption and metabolism of the main active constituents of Zushima (D). Nanjing: Nanjing University of Chinese Medicine
   Google Scholar
• Smith KS, Smith PL, Heady TN, et al. (2003). In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Chem Res Toxicol 16:123–8
   PubMed Web of Science ®Google Scholar
• Taskinen J, Ethell BT, Pihlavisto P, et al. (2003). Conjugation of catechols by recombinant human sulfotransferases, UDP-glucuronosyltransferases, and soluble catechol O-methyltransferase: structure-conjugation relationships and predictive models. Drug Metab Dispos 31:1187–97
   PubMed Web of Science ®Google Scholar
• Tenhunen J, Salminen M, Lundström K, et al. (1994). Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem 223:1049–59
   PubMedGoogle Scholar
• Tsuji E, Okazaki K, Takeda K. (2009). Crystal structures of rat catechol-O-methyltransferase complexed with coumarine-based inhibitor. Biochem Biophys Res Commun 378:494–7
   PubMed Web of Science ®Google Scholar
• Vieira-Coelho MA, Soares-da-Silva P. (1999). Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase. Brain Res 821:69–78
   PubMed Web of Science ®Google Scholar
• Wu L, Wang X, Xu W, et al. (2009). The structure and pharmacological functions of coumarins and their derivatives. Curr Med Chem 16:4236–60
   PubMed Web of Science ®Google Scholar
• Xia YL, Ge GB, Wang P, et al. (2015). Structural modifications at the C-4 position strongly affect the glucuronidation of 6,7-dihydroxycoumarins. Drug Metab Dispos 43:553–60
   PubMed Web of Science ®Google Scholar
• Xia YL, Liang SC, Zhu LL, et al. (2014). Identification and characterization of human UDP-glucuronosyltransferases responsible for the glucuronidation of fraxetin. Drug Metab Pharmacokinet 29:135–40
   PubMed Web of Science ®Google Scholar
• Zhang YY, Liu Y, Zhang JW, et al. (2009). Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel. Xenobiotica 39:283–92
   PubMed Web of Science ®Google Scholar